CD274 and cancer: The incidence of 3 to 4 TRAEs of cemiplimab was lower than the cost of chemotherapy (28% vs 39%)[25] (Table 1) retrospective investigation of cancers with high PD-L1 expression (≥90%) found a significant survival improvement in the group of tumors that received anti-PD-1 antibodies.[18] In light of the outcomes of the EMPOWER-Lung 01, for mNSCLC patients who have PD-L1 expression ≥ 50%, cemiplimab has been approved by the FDA as first-line treatment (Fig. 1).